Resources

2015

Mosquirix: Opinion on medicine for use outside EU

2015 ∙ STIKO

Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease

2015 ∙ Milagritos D. Tapia, Samba O. Sow, Fadima Cheick Haidara, Fatoumata Diallo, Moussa Doumbia, Godwin C. Enwere, Gandhali Paranjape, Jacques Hervé, Marie-Pierre Préziosi

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

2015 ∙ Andromachi Karachaliou, Andrew J. K. Conlan, Marie-Pierre Préziosi, Caroline Trotter

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

2015 ∙ WHO

Meningococcal A conjugate vaccine: updated guidance

2015 ∙ RTS,S Clinical Trials Partnership

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

2015 ∙ SAGE

Safety of pertussis vaccines in immunocompetent infants and children

2015 ∙ CAVEI

Chile - Standard Operating Procedure of the National Committee on Vaccines and Immunization Strategies

2015 ∙ SAGE

Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease

2015 ∙ SAGE

5255 results found

Mosquirix: Opinion on medicine for use outside EU

Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Meningococcal A conjugate vaccine: updated guidance

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

Safety of pertussis vaccines in immunocompetent infants and children

Chile - Standard Operating Procedure of the National Committee on Vaccines and Immunization Strategies

Duration of protection conferred by MenA conjugate vaccination in immunocompetent children (3 to 24 months of age) against serogroup A meningococcal disease

Efficacy of a single-dose MenA conjugate vaccination in immunocompetent children (9 to 24 months of age) against serogroup A meningococcal disease